Pharmaceutical Reimbursement Of Innovative Medicinal Products In Belgium

Are herbal medicinal products less teratogenic than Western pharmaceutical products.

AIM To determine the use and teratogenicity of herbal medicinal products (HMP). METHODS A retrospective study was conducted in a University hospital to compare the difference in the pattern of use and fetal outcomes between pregnant women who took HMP and Western pharmaceutical products (WPP). RESULTS From 1995 Jan to 2001 Dec, 61 and 372 women took HMP and WPP one month before or during th...

Restrictions on the reimbursement policy with regard to retail marketing of medicinal products in Poland.

On January 1, 2012, the law of 12 May 2011 on the reimbursement of medicines, food products of special nutritional purpose and medicinal products, intended to tighten up the reimbursement system, came into force in Poland. The new legislative act has significantly altered the previous principles of retail marketing of products subject to publicly financed reimbursement. First of all, the prices...

Pharmaceutical Pricing and Reimbursement: Canada

Incentives and pharmaceutical reimbursement reforms in Spain.

The aim of this paper is to assess whether cost containment has been affected by recent pharmaceutical reimbursement reforms that have been introduced in the Spanish health care system over the period 1996-2002, under the conservative Popular Party Government. Four main reimbursement policies can be observed in the Spanish pharmaceutical market after 1996, each of them largely unintegrated with...

Reimbursement of orphan drugs in Belgium: what (else) matters?

BACKGROUND Most orphan drugs do not meet traditional standards of cost-effectiveness. Yet, most orphan drugs are reimbursed, which implies that other factors are taken into account at the time of reimbursement. To increase accountability of decision-makers, there is a need for more transparency in the factors that play a role in reimbursement decisions of orphan drugs. Therefore, the aim of thi...